Crinetics Pharmaceuticals Inc.
News
Natixis Advisors LLC Raises Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Zolmax Natixis Advisors LLC boosted its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 18.4% during the 2nd quarter, Holdings Channel.com reports. The firm owned...\n more…
Natixis Advisors LLC Grows Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Ticker Report Natixis Advisors LLC raised its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 18.4% in the second quarter, according to the company in its most recent disclosure with the...\n more…
Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on September 10, 2024, the Compensation Committee of Crinetics' Board of Directors...\n more…
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Acquired by Bank of New York Mellon Corp
Zolmax Bank of New York Mellon Corp raised its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 30.3% during the 2nd quarter, according to its most recent Form 13F filing with the...\n more…
Brokerages Set Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) PT at $64.75
Ticker Report Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) has earned an average rating of "Moderate Buy" from the twelve research firms that are covering the company, Marketbeat Ratings...\n more…